Virtus ETF Advisers’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,779
| Closed | -$49.1K | – | 489 |
|
|
2024
Q3 | $49.1K | Buy |
1,779
+31
| +2% | +$856 | 0.02% | 442 |
|
|
2024
Q2 | $50.7K | Sell |
1,748
-397
| -19% | -$11.5K | 0.02% | 443 |
|
|
2024
Q1 | $95.6K | Sell |
2,145
-147
| -6% | -$6.56K | 0.05% | 371 |
|
|
2023
Q4 | $88.9K | Buy |
2,292
+859
| +60% | +$33.3K | 0.06% | 406 |
|
|
2023
Q3 | $42.1K | Sell |
1,433
-143
| -9% | -$4.2K | 0.03% | 420 |
|
|
2023
Q2 | $100K | Buy |
1,576
+155
| +11% | +$9.86K | 0.06% | 379 |
|
|
2023
Q1 | $67.1K | Sell |
1,421
-546
| -28% | -$25.8K | 0.04% | 405 |
|
|
2022
Q4 | $137K | Buy |
1,967
+811
| +70% | +$56.3K | 0.07% | 375 |
|
|
2022
Q3 | $169K | Buy |
1,156
+9
| +0.8% | +$1.32K | 0.07% | 336 |
|
|
2022
Q2 | $150K | Buy |
+1,147
| New | +$150K | 0.06% | 318 |
|